Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 20, 2000International Journal of Cancer

A prospective trial of midwest breast cancer patients: Ap53 gene mutation is the most important predictor of adverse outcome

View Full Paper
Ask AI
Bookmark
Share

Authors

HBHagen BlaszykMaine Medical CenterAHArndt HartmannUniversitätsklinikum ErlangenJCJulie M. CunninghamUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Blaszyk et al. (2000) studied this question.

synapsesocial.com/papers/6a1fdd613f3a87967f2e3ca0https://doi.org/10.1002/(sici)1097-0215(20000120)89:1<32::aid-ijc6>3.0.co;2-g
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.1998 · 58 citations
  2. 2Loss of Tumor Marker-Immunostaining Intensity on Stored Paraffin Slides of Breast Cancer1996 · 297 citations
  3. 3Nonparametric Estimation from Incomplete Observations1958 · 39,549 citations
  4. 4Pattern of p53 Gene Mutations in Breast Cancers of Women of the Midwestern United States1992 · 93 citations
  5. 5Structure and Function of the p53 Tumor Suppressor Gene: Clues for Rational Cancer Therapeutic Strategies1996 · 687 citations